Author(s):
Mitali M. Bodhankar, Adiba Daud Khan, Snehal J. Shrivastav, Shubham S. Gupta, Pranali S. Band
Email(s):
mit21_bod@yahoo.co.in , adiba8423@gmail.com , snehalshrivastav022@gmail.com , shubhamgupta0918@gmail.com , bandpranali14@gmail.com
DOI:
10.52711/0974-360X.2026.00619 
Address:
Mitali M. Bodhankar1*, Adiba Daud Khan1, Snehal J. Shrivastav2, Shubham S. Gupta1, Pranali S. Band3
1Department of Pharmaceutics, Gurunanak College of Pharmacy, Nagpur. RTMNU, Nagpur, 440026.
2Department of Pharmaceutical Chemistry, Gurunanak College of Pharmacy, Nagpur. RTMNU, Nagpur. 440026, Maharashtra, India.
3Department of Pharmacognosy, Gurunanak College of Pharmacy, Nagpur. RTMNU, Nagpur. 440026, India.
*Corresponding Author
Published In:
Volume - 19,
Issue - 9,
Year - 2026
ABSTRACT:
Colon-targeted drug delivery systems are a promising approach for the treatment of colonic diseases while reducing systemic side effects. The present study aimed to develop and evaluate pH-sensitive microparticles of Vancomycin hydrochloride using egg albumin as a biodegradable polymer and Eudragit S-100 as an enteric coating polymer. Microparticles were prepared by the emulsion solvent evaporation technique and subsequently coated to achieve colon-specific release. Drug–polymer compatibility was confirmed by FTIR analysis, indicating no significant interaction. The prepared formulations exhibited satisfactory percentage yield and drug entrapment efficiency, with the optimized formulation showing 97.46% yield and 74.6% entrapment efficiency. Particle size analysis revealed microparticles in the micron range, and zeta potential values indicated good formulation stability. In-vitro drug release studies demonstrated minimal release in gastric and intestinal conditions, followed by a significant increase at colonic pH. The presence of rat caecal contents further enhanced drug release. Stability studies showed minimal reduction in drug entrapment over three months, indicating good stability. Overall, the developed system provides an effective platform for colon-targeted delivery of Vancomycin hydrochloride and may improve therapeutic outcomes in colonic infections.
Cite this article:
Mitali M. Bodhankar, Adiba Daud Khan, Snehal J. Shrivastav, Shubham S. Gupta, Pranali S. Band. Development and Evaluation of pH-Sensitive Eudragit-Coated Albumin Microparticles for Colon-Targeted Delivery of Vancomycin Hydrochloride. Research Journal Pharmacy and Technology. 2026;19(9):4437-4. doi: 10.52711/0974-360X.2026.00619
Cite(Electronic):
Mitali M. Bodhankar, Adiba Daud Khan, Snehal J. Shrivastav, Shubham S. Gupta, Pranali S. Band. Development and Evaluation of pH-Sensitive Eudragit-Coated Albumin Microparticles for Colon-Targeted Delivery of Vancomycin Hydrochloride. Research Journal Pharmacy and Technology. 2026;19(9):4437-4. doi: 10.52711/0974-360X.2026.00619 Available on: https://rjptonline.org/AbstractView.aspx?PID=2026-19-9-65
5. REFERENCES:
1. Sinha VR, Kumria R. Microbially triggered drug delivery to the colon. Eur. J. Pharm. Sci. [Internet]. 2003 Jan 1 [cited 2026 Mar 17]; 18(1): 3–18. Available from: https://www.sciencedirect.com/science/article/abs/pii/S092809870200221X
2. Gupta A, Mittal A, Gupta AK. Colon Targeted Drug Delivery Systems -- A Review. Asian J. Pharm. Res. 2011; 1(2): 25–33.
3. Chourasia MK, Jain SK. Pharmaceutical approaches to colon targeted drug delivery systems. J. Pharm. Pharm. Sci. 2003; 6(1): 33–66.
4. Amidon S, Brown JE, Dave VS. Colon-Targeted Oral Drug Delivery Systems: Design Trends and Approaches. AAPS PharmSciTech. 2015; 16(4): 731–41.
5. Sirisha. Recent Advancements on Colon Targeted Drug Delivery Systems. Asian J. Pharm. Res. 2020; 10(4): 268–74.
6. Philip AK, Philip B. Colon targeted drug delivery systems: A review on primary and novel approaches. Oman Med. J. 2010; 25(2): 70–8.
7. Tawar MG, Chaudhari PD. Design and Dissolution Study of Colon Specific Drug Delivery System of Tinidazole. Res. J. Pharm. Technol. 2009; 2(4): 862–4.
8. Shah RS, Shah RR, Nitalikar MM, Magdum CS. Design, Development and Evaluation of Enteric Coated Tablets of Glimepiride. Asian J. Pharm. Res. 2017; 7(3): 155–64.
9. McCoubrey LE, Favaron A, Awad A, Orlu M, Gaisford S, Basit AW. Colonic drug delivery: Formulating the next generation of colon-targeted therapeutics. J. Control. Release [Internet]. 2023;353(November 2022): 1107–26. Available from: https://doi.org/10.1016/j.jconrel.2022.12.029
10. D’Souza JI, More HN. Topical Anti-Inflammatory Gels of Fluocinolone Acetonide Entrapped in Eudragit-Based Microsponge Delivery System. Res. J. Pharm. Technol. 2008; 1(4): 502–6.
11. Sivakumar SM, Nirmala L, Swarnalakshmi R, Sivakumar L, Anilbabu B, Shanmugarajan TS, et al. Preparation and In Vitro Evaluation of Hepatitis B Vaccine Encapsulated Chitosan Microparticles. Res. J. Pharm. Technol. 2009;2(1):117–9.
12. Gvozdeva Y, Staynova R. pH-Dependent Drug Delivery Systems for Ulcerative Colitis Treatment. Pharmaceutics. 2025; 17(2).
13. Varde NK, Pack DW. Microparticles for controlled release drug delivery. Expert Opin. Biol. Ther. 2004; 4(1): 35–51.
14. Sonkar SK, Lanjhiyana SK. Formulation and Evaluation of Methotrexate-Loaded Multiparticulate System for Colon Targeting: In Vitro and Surface Morphology. Res. J. Pharm. Technol. 2019; 12(5): 2067–74.
15. Sheik R, Gopinath P. Detection of Vancomycin Resistance among Clinical Isolates of Enterococci. Res. J. Pharm. Technol. 2016;9(12):2106–8.
16. Shendge RS, Zalte TS, Khade SB. Polymeric microparticles redefining the landscape of colon-targeted delivery: A contemporary update. Eur. J. Med. Chem. Reports [Internet]. 2024;11(February):100156. Available from: https://doi.org/10.1016/j.ejmcr.2024.100156
17. Kumari A, Jain A, Hurkat P, Tiwari A, Jain SK. Eudragit S100 coated microsponges for Colon targeting of prednisolone. Drug Dev. Ind. Pharm. [Internet]. 2018;44(6):902–13. Available from: http://dx.doi.org/10.1080/03639045.2017.1420079
18. Friend DR. Colon-specific drug delivery. Adv. Drug Deliv. Rev. 1991; 7(1): 149–99.
19. Hajare AA, Shetty YT, Mali MN, Sarvagod SM. Characterization of Melt (Fusion) Solid Dispersions of Nifedipine. Res. J. Pharm. Technol. 2008; 1(3): 230–4.
20. Raj BS, Shanthi, Nair RS, Samraj PI, Vidya. Formulation and evaluation of coated microparticles for colon targeting. J. Appl. Pharm. Sci. 2013; 3(8 SUPPL):68–74.
21. Patel P, Dhake A. Design and development of colon specific microparticles for chronotherapy of hypertension. J. Pharm. Bioallied Sci. 2012; 4(SUPPL.): 33–4.
22. Shivhare UD, Chhabra GS, Mathur VB, Patel SB. Microencapsulation of acyclovir into Eudragit S100 using emulsion-solvent evaporation method. Res J Pharm Technol. 2011; 4(4): 652–8.
23. Singh A et al. Sandeep Atram 3. Asian J. Pharm. Res. Dev. 2023; 11(4): 36–45.
24. Ray MR, Bose SK, Sengupta K. Design, Development and In Vitro Evaluation of Directly Compressed Sustained Release Matrix Tablet of Famotidine. Res. J. Pharm. Technol. 2008; 1(3): 175–8.
25. Elkhodairy KA, Afifi SA, Zakaria AS. A promising approach to provide appropriate colon target drug delivery systems of vancomycin HCL: Pharmaceutical and Microbiological Studies. Biomed Res. Int. 2014;2014.
26. Pharmacopoeia US. Vancomycine hydrocholoride monograph. USP-43.: NF-38.
27. Beckett AH, Stenlake JB. Practical pharmaceutical chemistry: Part two. Athlone Press University of London; 1976.
28. Lamprecht A, Schafer U, Lehr C-M. Size-dependent bioadhesion of micro-and nanoparticulate carriers to the inflamed colonic mucosa. Pharm. Res. 2001; 18(6): 788–93.
29. Honary S, Zahir F. Effect of zeta potential on the properties of nano-drug delivery systems-a review (Part 2). Trop. J. Pharm. Res. 2013; 12(2): 265–73.
30. den Mooter G. Colon drug delivery. Expert Opin. Drug Deliv. 2006; 3(1): 111–25.